Despite these successes, little is known of how the presence of low-dose IL2 and the consequent expansion of Tregs could affect beneficial effector immune responses when patients receiving the treatment develop acute bacterial infections, such as S. aureus arthritis. The gene discussed is IL2; the disease is Arthritis.